The Food and Drug Administration has put the final regulatory pieces together for South Koreanultrasound vendor Medison. After a rather prolonged wait, theagency cleared Medison's SonoAce 4800 scanner, a gray-scale Dopplersystem that will be Medison's
The Food and Drug Administration has put the final regulatory pieces together for South Koreanultrasound vendor Medison. After a rather prolonged wait, theagency cleared Medison's SonoAce 4800 scanner, a gray-scale Dopplersystem that will be Medison's premium scanner until the introductionof a color-flow Doppler unit some time in the future, accordingto Mark Hayward, president of Medison's U.S. subsidiary in Pleasanton,CA. Two other Medison systems were cleared last year, with SonoAce4800 the last of the vendor's scanners in the FDA's review process(SCAN 2/2/94).
SonoAce 4800 is a convex, linear, mechanical and pulsed Dopplersystem that will be targeted at vascular and abdominal applications.Medison will handle direct sales and will market the system primarilyto the in-office ultrasound market. List price of SonoAce 4800with Doppler, two probes and a printer is $38,900. Medison marketsa color-flow Doppler unit in Korea and plans to bring that scannerto the U.S., Hayward said.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.